.jpg "Cryolife (NYSE: CRY)")
In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Cryolife (CRY), with a price target of $32. The company’s shares opened today at $28.35.
Kalia wrote:
“We continue to be strongly bullish on CryoLife. Our thesis is predicated on a few simple things: 1) Our belief in the New product intros over the next few years. The stock currently trades at ~4x Sales, which is a discount to the 5.2x multiple for the broader space. For sure, the volatility in CryoLife stock will not be as much as other players in the space. But this is a steady eddy story.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 10.3% and a 56.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cryolife with a $32 average price target.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $1.55 million. In comparison, last year the company had a GAAP net loss of $3.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
